Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes.
Jiao Y, Davis JE, Rautela J, Carrington EM, Ludford-Menting MJ, Goh W, Delconte RB, Souza-Fonseca-Guimaraes F, Koldej R, Gray D, Huang D, Kile BT, Lew AM, Ritchie DS, Huntington ND. Jiao Y, et al. Among authors: huang d. Cell Death Differ. 2019 Aug;26(8):1516-1530. doi: 10.1038/s41418-018-0228-y. Epub 2018 Nov 12. Cell Death Differ. 2019. PMID: 30420758 Free PMC article.
Targeting BCL2 for the treatment of lymphoid malignancies.
Anderson MA, Huang D, Roberts A. Anderson MA, et al. Among authors: huang d. Semin Hematol. 2014 Jul;51(3):219-27. doi: 10.1053/j.seminhematol.2014.05.008. Epub 2014 May 15. Semin Hematol. 2014. PMID: 25048785 Free article. Review.
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH. Moujalled DM, et al. Among authors: huang d. Leukemia. 2019 Apr;33(4):905-917. doi: 10.1038/s41375-018-0261-3. Epub 2018 Sep 10. Leukemia. 2019. PMID: 30214012 Free PMC article.
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Thijssen R, Tian L, Anderson MA, Flensburg C, Jarratt A, Garnham AL, Jabbari JS, Peng H, Lew TE, Teh CE, Gouil Q, Georgiou A, Tan T, Djajawi TM, Tam CS, Seymour JF, Blombery P, Gray DHD, Majewski IJ, Ritchie ME, Roberts AW, Huang DCS. Thijssen R, et al. Among authors: huang dcs. Blood. 2022 Nov 17;140(20):2127-2141. doi: 10.1182/blood.2022016040. Blood. 2022. PMID: 35709339 Free PMC article.
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.
Teh CE, Peng H, Luo MX, Tan T, Trussart M, Howson LJ, Chua CC, Muttiah C, Brown F, Ritchie ME, Wei AH, Roberts AW, Bryant VL, Anderson MA, Lindeman GJ, Huang DCS, Thijssen R, Gray DHD. Teh CE, et al. Among authors: huang dcs. Blood Adv. 2023 Jun 27;7(12):2733-2745. doi: 10.1182/bloodadvances.2022008221. Blood Adv. 2023. PMID: 36521105 Free PMC article.
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, Litalien V, Thompson E, Morley T, MacRaild S, Tiong IS, Morris R, Dun K, Zordan A, Shah J, Banquet S, Halilovic E, Morris E, Herold MJ, Lessene G, Adams JM, Huang DCS, Roberts AW, Blombery P, Wei AH. Moujalled DM, et al. Blood. 2023 Feb 9;141(6):634-644. doi: 10.1182/blood.2022016090. Blood. 2023. PMID: 36219880 Free PMC article.
14,444 results
You have reached the last available page of results. Please see the User Guide for more information.